Expert Review of Clinical Pharmacology最新文献_第5页

The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease. 慢性阻塞性肺疾病患者吸入磷酸二酯酶抑制剂的必要性

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-12-05 DOI: 10.1080/17512433.2024.2438187

Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera

{"title":"The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease.","authors":"Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera","doi":"10.1080/17512433.2024.2438187","DOIUrl":"10.1080/17512433.2024.2438187","url":null,"abstract":"Introduction: The therapeutic implications of phosphodiesterase (PDE) inhibitors have attracted interest because PDEs are regarded as an intracellular target to be exploited for therapeutic advancements in the treatment of COPD. At present, the only approved approach for the treatment of COPD with PDE inhibitors is the use of an oral PDE4 inhibitor. However, this treatment is not widely employed, primarily due to the narrow therapeutic index associated with oral PDE4 inhibitors, which significantly limits the tolerable dose. The inhalation route represents a viable alternative to the oral route for improving the therapeutic index of PDE4 inhibitors.Areas covered: The development of inhaled PDE4 inhibitors, with a focus on tanimilast and ensifentrine, the latter of which is a dual PDE3/PDE4 inhibitor.Expert opinion: The inhalation route offers several advantages regarding the delivery of PDE inhibitors for the management of COPD. Tanimilast and ensifentrine have been shown to improve lung function, reduce exacerbations and enhance quality of life in COPD patients. However, it has not yet been determined which type of COPD patient might benefit more from inhaled PDE4 inhibitors, and it remains unclear whether concomitant inhibition of PDE3 and PDE4 confers a significant benefit compared to blocking PDE4 alone in COPD.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1149-1161"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A scoping review of the clinical utility of adverse drug reaction causality analysis tools for use in the hospital setting. 药物不良反应因果关系分析工具在医院环境中的临床应用范围综述。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1080/17512433.2024.2429677

Benjamin Deutscher, Keshia De Guzman, Adam La Caze, Nazanin Falconer

{"title":"A scoping review of the clinical utility of adverse drug reaction causality analysis tools for use in the hospital setting.","authors":"Benjamin Deutscher, Keshia De Guzman, Adam La Caze, Nazanin Falconer","doi":"10.1080/17512433.2024.2429677","DOIUrl":"10.1080/17512433.2024.2429677","url":null,"abstract":"Introduction: Identification and monitoring of adverse drug reactions (ADRs) and interventions to reduce ADRs are essential for patient safety in hospitals. Causality analysis (CA) is an approach that helps to determine a causal link between medication and patient harm (i.e. an ADR). While numerous CA tools exist, there is no gold standard.Areas covered: Five online databases were searched to identify studies that evaluated the potential clinical utility of CA tools for ADRs. CA tools were mapped against the Bradford Hill (BH) criteria and included if they adhered to the first seven criteria proposed by BH. Upon the database search, 550 studies were identified, with 41 studies being selected that looked at tools mapped to BH. Thirty-four different CA tools were identified in the included studies.Expert opinion: Naranjo and WHO-UMC were the most reported CA tools for studies examining inter-rater and intra-rater reliability. Naranjo commonly received a 'fair' agreement level while WHO-UMC received a 'substantial' agreement level between raters. Along with kappa statistics, time using the CA tool was also analyzed, with WHO-UMC being the most time-efficient. There does not appear to be one CA tool that can be applied universally to pharmacovigilance efforts in hospital in-patient settings.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1127-1148"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The search for blood biomarkers useful in treating atopic dermatitis patients. 对治疗特应性皮炎患者有用的血液生物标志物的研究。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-12-16 DOI: 10.1080/17512433.2024.2438192

Kenji Izuhara, Satoshi Nunomura, Takeshi Nakahara, Daisuke Onozuka

{"title":"The search for blood biomarkers useful in treating atopic dermatitis patients.","authors":"Kenji Izuhara, Satoshi Nunomura, Takeshi Nakahara, Daisuke Onozuka","doi":"10.1080/17512433.2024.2438192","DOIUrl":"10.1080/17512433.2024.2438192","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is diagnosed based on clinical signs and symptoms as well as on a clinical course lacking distinct laboratory or histological features; however, the recent appearance of molecularly targeted drugs against AD urges us to try to discover and develop biomarkers useful for treating AD patients.Areas covered: This article commenced with a targeted PubMed search using 'atopic dermatitis' and 'biomarker' as keywords. We combined the findings from the B-PAD study that we have recently published and summarized data, particularly those recently published.Expert opinion: Many cells and molecules are listed as potential biomarkers of AD, most of which are type 2 mediators. Among them, CCL17/TARC is now thought to be the most reliable biomarker of AD. During the B-PAD study, we recently found that three biomarkers - squamous cell carcinoma antigen 2 (SCCA2), CCL26/eotaxin-3, and lactose dehydrogenase (LDH) - are better able than CCL17/TARC to assess the clinical severity and disease activity of AD. Moreover, although several biomarkers showed good ability to monitor the efficacy of molecularly targeted drugs against AD. More studies on the discovery and development of biomarkers of AD are awaited to refine treatments for AD patients.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1163-1172"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changing landscapes and increasing relevance of immunotherapy in localized MSI-H gastric adenocarcinoma. 局部MSI-H型胃腺癌免疫治疗前景的变化和相关性的提高。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-12-10 DOI: 10.1080/17512433.2024.2438178

Jane E Rogers, Jaffer A Ajani

引用次数: 0

The use of oral GnRH antagonists to inhibit the LH surge in women undergoing ovarian stimulation for in vitro fertilization. 使用口服 GnRH 拮抗剂抑制体外受精卵巢刺激妇女的 LH 激增。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-11-11 DOI: 10.1080/17512433.2024.2428342

Valentina Grisendi, Giovanni Grandi, Martina Capuzzo, Antonio La Marca

引用次数: 0

Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview. Avacopan作为anca相关血管炎的附加治疗：药理学综述。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-11-29 DOI: 10.1080/17512433.2024.2432500

Vladimir Tesar, Jan Miroslav Hartinger, Zdenka Hruskova

{"title":"Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview.","authors":"Vladimir Tesar, Jan Miroslav Hartinger, Zdenka Hruskova","doi":"10.1080/17512433.2024.2432500","DOIUrl":"10.1080/17512433.2024.2432500","url":null,"abstract":"Introduction: ANCA-associated vasculitis (AAV) is a rare, life-threatening disease which may result in serious pulmonary and kidney damage. Cyclophosphamide or rituximab and high-dose glucocorticoids significantly improved patient outcomes, but at the expense of severe complications. Moreover, many patients still relapse and bear a significant burden of both disease- and treatment-related complications. Alternative complement pathway and C5a receptor signaling were demonstrated to play an important role in AAV pathogenesis. Avacopan is selective C5a receptor inhibitor successfully tested in renal AAV as glucocorticoid-sparing agent.Areas covered: Pharmacokinetic/pharmacodynamic properties, clinical efficacy and safety of avacopan, available clinical trials and real-world experience with avacopan.Expert opinion: In the phase 3 trial avacopan was shown to be non-inferior at six and superior at 12 months compared to high-dose glucocorticoids and either cyclophosphamide or rituximab in patients with active AAV. Treatment with avacopan was well tolerated and associated with improved quality of life. In patients with severe renal AAV, renal function improved more in avacopan-treated than in high-dose glucocorticoid-treated patients. Avacopan could thus replace high-dose glucocorticoids to avoid glucocorticoid-related toxicity and to improve long term renal outcome. As avacopan is CYP 3A4 inhibitor and substrate, drug-drug interactions must be considered during the treatment.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1099-1113"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methenamine Hippurate in UTI management: a reemerging pharmacological strategy. 尿路感染管理中的盐酸甲基苯丙胺：一种重新出现的药理学策略。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-12-23 DOI: 10.1080/17512433.2024.2445621

Mehwash Nadeem, Hashim Hashim

引用次数: 0

Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity. 转移性黑色素瘤的免疫检查点抑制：在高毒性下实现高疗效。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-11-21 DOI: 10.1080/17512433.2024.2431513

Joy Justice, Roma A Kankaria, Douglas B Johnson

引用次数: 0

Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists. 了解偏头痛治疗的疗效和耐受性：深入研究 CGRP 拮抗剂。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1080/17512433.2024.2417655

Marta Waliszewska-Prosół, Bianca Raffaelli, Marcin Straburzyński, Paolo Martelletti

{"title":"Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists.","authors":"Marta Waliszewska-Prosół, Bianca Raffaelli, Marcin Straburzyński, Paolo Martelletti","doi":"10.1080/17512433.2024.2417655","DOIUrl":"10.1080/17512433.2024.2417655","url":null,"abstract":"Introduction: The discovery of the role of the calcitonin gene-related peptide (CGPR) in migraine pathogenesis ushered in a new era in headache medicine. This evidence led to the development of small-molecule CGRP receptor antagonists and monoclonal antibodies targeting either CGRP or its receptor.Areas covered: We will present selected aspects of the role of CGRP in the pathogenesis of migraine, the efficacy of CGRP-targeted treatment, and the still-open questions regarding the practical application of CGRP antagonists in headache medicine.Expert opinion: CGRP-targeting drugs represent a transformative approach to migraine treatment, offering superior efficacy and tolerability compared to traditional therapies, they are a helpful addition to the treatment arsenal but also have their flaws and require further observation. Their availability provides new hope for migraine patients, particularly those who have not responded adequately to conventional treatments. Future directions for migraine care planning, especially for chronic migraine and medication-overuse headache, should include universal access to these specific and effective forms of therapy to prevent complications from the disease and its negative effects in many aspects of a patient's life.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1039-1051"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire! 塞马鲁肽与 2 型糖尿病患者的戒烟：无烟不成火！

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-11-01 Epub Date: 2024-10-21 DOI: 10.1080/17512433.2024.2418398

Djordje S Popovic, Dimitrios Patoulias, Theocharis Koufakis, Paschalis Karakasis, Ieva Ruža, Nikolaos Papanas

{"title":"Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!","authors":"Djordje S Popovic, Dimitrios Patoulias, Theocharis Koufakis, Paschalis Karakasis, Ieva Ruža, Nikolaos Papanas","doi":"10.1080/17512433.2024.2418398","DOIUrl":"10.1080/17512433.2024.2418398","url":null,"abstract":"Tobacco use represents the leading preventable risk factor for premature deaths worldwide. A meta-analysis of 74 epidemiological studies, including 3.2 million individuals with type 2 diabetes mellitus (T2DM) from 33 countries, reported a pooled prevalence of smoking of 20.8% among individuals with T2DM. Cigarette smoking further aggravates existing deleterious vascular effects of T2DM. Namely, chronic hyperglycemia and exposure to cigarette smoke cause additive injurious effect on the endothelium, leading to an acceleration of vascular complications seen in persons with T2DM and tobacco use disorders (TUD). In a recent study, Wang and colleagues found that semaglutide use was associated with a significantly lower risk for medical encounters for TUD, when compared to other antidiabetic drug classes; indeed, this effect was strongest compared with insulins and weakest compared with other glucagon-like peptide-1 receptor agonists. Semaglutide was associated with reduced smoking cessation medication prescriptions and counseling. Similar findings were observed irrespective of the presence of obesity. Therefore, semaglutide use might be useful in terms of smoking cessation among individuals with T2DM, thus offering an additional benefit for this constantly growing population. However, those interesting findings should be confirmed through dedicated, large-scale randomized controlled trials.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1009-1012"},"PeriodicalIF":3.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0